German regulatory agency approves Rizaport to treat acute migraines
Rizaport, 5 mg and 10 mg, is an oral thin film formulation of rizatriptan benzoate. It is being developed by RedHill Biopharma and IntelGenx. It is the first
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.